Abstracts tagged "Connective tissue diseases"

Abstract Number: 1351 • 2016 ACR/ARHP Annual Meeting
Mortality and Prognostic Factors of Pneumocystis Pneumonia in Patients with Connective Tissue Diseases
Mitsuhiro Akiyama¹, Yuko Kaneko² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is one of the severe opportunistic infections in immunocompromised patients. PCP is still a leading cause of death in patients with…
Abstract Number: 1863 • 2016 ACR/ARHP Annual Meeting
Non-Invasive Investigation of Perfusion, Microvascular Structure, Erythema, Oxidative Stress and Oxygenation in Healthy Controls and in Patients with Primary and Secondary Raynaud’s Phenomenon
Andrea Murray^1,2, Tonia Moore³, Joanne Manning⁴, Ian Poxon², Graham Dinsdale¹, Michael Berks⁵, Sarah Leggett⁶, Mark Dickinson² and Ariane L. Herrick¹, ¹Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ²Photon Science institute, University of Manchester, Manchester, United Kingdom, ³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Salford, United Kingdom, ⁴Rheumatology Department, Salford Royal NHS Foundation Trust, Salford, United Kingdom, ⁵Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ⁶Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose: It is well established that measurements of cutaneous microvascular dysfunction (measured with laser Doppler imaging [LDI]) and structural abnormality (measured with nailfold capillaroscopy [NC])…
Abstract Number: 1867 • 2016 ACR/ARHP Annual Meeting
An Abnormal Nailfold Capillaroscopy Pattern Is Common in Patients with Connective Tissue Disease and Is Associated with Pulmonary and Oesophageal Involvement, Even in the Absence of Systemic Sclerosis
Anniek M van Roon¹, Cato C Huisman¹, Arie M van Roon¹, Alja J Stel², Andries J Smit¹, Hendrika Bootsma² and Douwe J Mulder¹, ¹Internal Medicine - division Vascular Diseases, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: RP is a common symptom of CTD. Nailfold capillary microscopy (NCM) has previously been shown to be associated with disease severity and internal organ…
Abstract Number: 2806 • 2016 ACR/ARHP Annual Meeting
A Type-I Interferon Signature Is Associated with Autoantibody Profiles in Connective Tissue Diseases: Results from the Lupus Extended Autoimmune Phenotype (LEAP) Study
John A. Reynolds^1,2, Mumtaz Khan³, Tracy A. Briggs⁴, Gillian Rice⁵, Yanick Crow⁵, Ben Parker⁶ and Ian N. Bruce^1,7, ¹NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ³Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ⁴Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁵Manchester Academic Health Science Centre, Institute of Human Development, University of Manchester, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁷Central Manchester University Hospital NHS Foundation Trust and Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
Background/Purpose: Type I interferon has been implicated in the pathogenesis of systemic lupus erythematosus (SLE), but much less is known about its role in other…
Abstract Number: 2907 • 2016 ACR/ARHP Annual Meeting
Serum KL-6 Levels in Interstitial Lung Diseases (ILDs) Associated to Connective Tissue Diseases (CTDs)
Lise Moreer¹, Hilario Nunes¹, Louise Bondeelle¹, Yurdagul Uzunhan¹, Pascale Ghillani-Dalbin², Dominique Valeyre¹, Lucile Musset³ and Makoto Miyara³, ¹Pulmonary diseases department, Avicenne Hospital (AP-HP), Bobigny, France, ²Department of Immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ³Department of immunology, Pitié-Salpêtrière Hospital (AP-HP), Paris, France
Background/Purpose: ILD is a frequent and potentially severe complication of CTDs. The course of ILD can be difficult to predict in this setting. The term…
Abstract Number: 44 • 2015 ACR/ARHP Annual Meeting
The Prevalence of Depression and Anxiety in a Cross-Section of Rheumatological Conditions
Faith Matcham¹, Nicola J. Gullick², Matthew Hotopf³, Sam Norton⁴, Sophia Steer⁵ and James Galloway⁶, ¹Psychological Medicine Clinical Academic Group, King's College London, London, United Kingdom, ²Rheumatology, Department of Rheumatology, King`s College Hospital NHS Foundation Trust, London, United Kingdom, ³Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom, ⁴Institute of Psychiatry, King's College London, London, United Kingdom, ⁵Rheumatology Dept, Kings College Hospital, London, United Kingdom, ⁶Academic Department of Rheumatology, King´s College London, London, United Kingdom
Background/Purpose: Depression and anxiety have detrimental effects on quality-of-life, treatment response and disease outcomes. Whilst psychological morbidity has been described in individual rheumatic diseases, less…
Abstract Number: 1874 • 2015 ACR/ARHP Annual Meeting
Impact of Socioeconomic Status on Survival in Connective Tissue Disease Associated and Idiopathic Pulmonary Arterial Hypertension
Helen Jin¹, John T. Granton², John Thenganatt³, Jakov Moric³, Ambika Gupta¹, Amie T. Kron¹, Cathy Chau¹ and Sindhu R. Johnson¹, ¹Toronto Scleroderma Program, Toronto Western Hospital, Mount Sinai Hospital, University of Toronto, University Health Network Pulmonary Hypertension Programme, Toronto, ON, Canada, ²Medicine, Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada, ³Univeristiy Health Network Pulmonary Hypertension Programme, Toronto General Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Poorer health outcomes for persons with chronic diseases have been reported in association with lower socioeconomic status (SES). No such evaluation exists for patients…
Abstract Number: 1894 • 2015 ACR/ARHP Annual Meeting
Calcium Channel Blockers Are More Effective in the Treatment of Primary Raynaud’s Phenomenon Compared to Secondary: A Meta-Analyis
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Peter Tugwell⁶, Jordi Pardo⁷, Elizabeth Ghogomu⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of calcium channel blockers (CCBs) versus placebo for the treatment of Raynaud's phenomenon (RP) comparing primary to secondary…
Abstract Number: 2147 • 2014 ACR/ARHP Annual Meeting
Automatically Extracted Quantitative Biomarkers for Assessing Connective Tissue Disease Using Nailfold Capillaroscopy
Michael Berks¹, Graham Dinsdale², Andrea Murray², Tonia Moore³, Chris Taylor¹ and Ariane Herrick², ¹Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ²Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom
Background/Purpose Videomicroscopy can capture high-magnification images of nailfold capillaries, allowing non-invasive assessment of microvasculature change indicative of connective tissue disease. Whilst images may be qualitatively…
Abstract Number: 1810 • 2014 ACR/ARHP Annual Meeting
Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety, and Wasted Health Care Resources
Sahar Eivaz Mohammadi¹, Imam H Shaik¹, Parag Chevli¹, Fernando Gonzalez-Ibarra¹, Sohini Sarkar¹, Saurav Acharya¹, Prerna Dogra¹, Hesam Hekmatjou², Maushmi Savjani², Waheed Abdul² and Valentin Marian³, ¹Internal Medicine, Jersey City Medical Center-Barnabas Health, Jersey City, NJ, ²Internal Medicine, St. George's University SOM, St. George's, Grenada, ³Rheumatology, Jersey City Medical Center-Barnabas Health, Jersey City, NJ
Background/Purpose: Results of serologic tests for autoantibodies, including tests for Antinuclear antibodies (ANAs) and antibodies to specific nuclear antigens such as double-stranded DNA (dsDNA), play…
Abstract Number: 1419 • 2014 ACR/ARHP Annual Meeting
Rituximab Use in Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience
Sandra Chartrand^1,2, Jeffery J. Swigris³, Lina Peykova² and Aryeh Fischer⁴, ¹Rheumatology, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada, ²Rheumatology, National Jewish Health, Denver, CO, ³Autoimmune Lung Center, National Jewish Health, Denver, CO, ⁴Rheumatology / ILD Program, National Jewish Health, Denver, CO
Background/Purpose: Small series have suggested that rituximab (RTX) may be effective as rescue-therapy for connective tissue disease-associated interstitial lung disease (CTD-ILD). We sought to describe…
Abstract Number: 1074 • 2014 ACR/ARHP Annual Meeting
A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases
Jason J Lee¹ and Janet E. Pope², ¹Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ²St Joseph Health Care, London, ON, Canada
Background/Purpose: We performed a meta-analysis investigating the risk of developing deep vein thrombosis (DVT) and/or pulmonary embolisms (PE) in patients with inflammatory arthritis, vasculitis, and…
Abstract Number: 875 • 2014 ACR/ARHP Annual Meeting
Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials
Rennie L. Rhee¹, Nicole B. Gabler², Amy Praestgaard², Peter A. Merkel³ and Steven M. Kawut⁴, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pulmonary and Critical Care, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Recent studies have shown that therapies for pulmonary arterial hypertension (PAH) improve exercise capacity, but subgroup analyses suggest that these therapies may be less…
Abstract Number: 2637 • 2013 ACR/ARHP Annual Meeting
Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis
Luca Quartuccio¹, Miriam Isola², Laura Corazza³, Soledad Retamozo⁴, Manal Abdel-Moneim El-Menyawi⁵, Elisa Gremese⁶, Marco Sebastiani⁷, Nicolo Pipitone⁸, Teresa Urraro⁹, Vincenza Conteduca¹⁰, Christos Koutsianas¹¹, Benjamin Terrier¹², Mostafa Naguib Zoheir¹³, Alessandra Ghinoi¹⁴, Davide Filippini¹⁵, Francesco Saccardo¹⁶, Mohamed Nabil Salem¹⁷, Salvatore Scarpato¹⁸, Paolo Fraticelli¹⁹, Antonio Tavoni²⁰, Eleonora Catarsi²¹, Cesare Mazzaro²², Pietro Pioltelli²³, Mervat Matar⁵, Patrizia Scaini²⁴, Matija Tomsic²⁵, Norihiro Nishimoto^26,27, Dimitrios Vassilopoulos²⁸, Michael Voulgarelis²⁹, Gaafar M. Ragab³⁰, Carlo Salvarani³¹, Armando Gabrielli³², Patrice Cacoub³³, Loic Guillevin³⁴, Domenico Sansonno³⁵, Anna Linda Zignego³⁶, Gianfranco Ferraccioli⁶, Athanasios G. Tzioufas³⁷, Manuel Ramos-Casals³⁸, Clodoveo Ferri³⁹, Maurizio Pietrogrande⁴⁰, Giuseppe Monti¹⁶, Massimo Galli⁴¹, Stefano Bombardieri⁴² and Salvatore De Vita⁴³, ¹Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ²Institute of Statistics, DSMB, University of Udine, Udine, Italy, ³Rheumatology Clinic, University of Udine, Udine, Italy, ⁴Laboratorio de Enfermedades Autoinmunes Josep Font, IDIBAPS, Hospital Clínic, Barcelona, Spain, ⁵Faculty of Medicine, Cairo, Egypt, ⁶Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ⁷Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁸Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, ⁹Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁰Department of Internal Medicine and Clinical Oncology, University of Bari, Bari, Italy, ¹¹Department of Pathophysiology, Medical School of Athens, Athens, Greece, ¹²Internal Medicine, Cochin University Hospital, Paris, France, ¹³Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology, Arcispedale S Maria Nuova, Reggio Emilia, Italy, ¹⁵Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, ¹⁶Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, ¹⁷Faculty of Medicine, Beni Swafe University, Beni Swafe, Egypt, ¹⁸Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, ¹⁹Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, ²⁰University of Pisa, Immunoallergology Unit, Pisa, Italy, ²¹Department of Internal Medicine, Section of Immunoallergology, University of Pisa, Pisa, Italy, ²²Department of Internal Medicine, Pordenone General Hospital, Pordenone, Italy, ²³Hematology, S.Gerardo Hospital, Monza, Italy, ²⁴Nephrology, Spedali Civili di Brescia, Brescia, Italy, ²⁵Department of Rheumatology, University Medical Centre Ljubjana, Ljubljana, Slovenia, ²⁶Laboratory of Immune Regulation, Wakayama Medical University, Ibaraki, Japan, ²⁷Osaka Rheumatology Clinic, Osaka, Japan, ²⁸2nd Department of Medicine, Athens University School of Medicine, Athens, Greece, ²⁹School of Medicine, University, Department of Pathophysiology, Athens, Greece, ³⁰Int Medicine Hosp/Rheum&Immun, Faculty of Medicine, Cairo University, Giza, Egypt, ³¹Rheumatology, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, ³²Scienze Cliniche e Molecolari, Università Politecnica delle Marche, Ancona, Italy, ³³Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France, ³⁴Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, ³⁵Section of Internal Medicine and Clinical Oncology, Department of Biomedical Sciences and Human Oncology, University of Bari, Medical School, Bari, Italy, ³⁶University of Florence, Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ³⁷Pathophysiology, School of Medicine, National University of Athens, Athens, Greece, ³⁸Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ³⁹Department of Internal Medicine, University of Modena and Reggio Emilia, Modena, Italy, ⁴⁰Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, ⁴¹Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy, ⁴²Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴³Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: preliminary Classification Criteria for cryoglobulinemic vasculitis (CV) have been developed in 2011 by an European cooperative study, with an adequate methodology in a large…
Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting
Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995
Dörte Huscher¹, Katinka Albrecht², Katja Thiele², Sascha Bischoff², Jutta G. Richter³, Ina Kötter⁴, Wolfgang Ochs⁵ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, ⁵Rheumatologist in private practice, Bayreuth, Germany
Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].